News

International investors boost Smartvel’s capital to increase its growth

Smartvel, a Spanish startup provider of destination content solutions for the tourism sector, has closed its second round of investment worth 1.05 million dollars, which will allow the tech company to continue to advance through the fast growing path that it has been maintaining thanks to its innovative technology based on Big Data, capable of collecting updated content from any destination in the world.

| Read more |

AELIX Therapeutics and Gilead Sciences Enter into a Clinical Research Collaboration Agreement to Evaluate a Therapeutic Vaccine and TLR7 Agonist Regimen for HIV Cure

AELIX Therapeutics S.L. (“AELIX”), a clinical-stage biotechnology company specialized in the discovery and development of immunotherapies for HIV infection, today announces that it has entered into a clinical research collaboration with Gilead Sciences, Inc. (“Gilead”), a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need, to jointly evaluate proprietary investigational products in a strategic clinical study aimed at achieving a functional cure of HIV infection.

| Read more |

NuMat Medtech secures a €530,000 round of investment

NuMat Medtech, a medical technology company based at the Balearic Technological Innovation Park (ParcBIT) and involved in developing coatings for medical implants, today announces a €530,000 round of capital finance. NuMat will use the funds secured to make preclinical studies of its coatings on various types of implant and to strengthen its strategic alliances with important international players in the dental and orthopaedics industry.

| Read more |

Minoryx Therapeutics raises €21.3M in Series B funding round

Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces the completion of a Series B funding round of €21.3M. The proceeds will enable the company to expand the list of indications for its lead compound, MIN-102, as well as to conduct a new clinical trial for a second orphan central nervous system (CNS) indication.

| Read more |

ABAC Therapeutics Announces €16 Million Series A to Develop Therapeutic Solutions to Fight Antibiotic-Resistant Bacteria

ABAC Therapeutics (ABAC), a leader in pathogen-specific antibiotics, announced today the closing of a €16 million Series A round. The financing was led by Pontifax with participation from the Global Health Science Fund (jointly established by Quark Venture Inc. and GF Securities), Caixa Capital Risc, Debiopharm Innovation Fund and the existing investor Ferrer.

| Read more |